Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8CGUV)

• Drug Name: MCLA-145 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM8CGUV

Molecule-Related Drug Atlas

Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urelumab	DM6RTVG	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[4]
Anti-CD137	DMHVZ27	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
MG7-CART	DME6PB0	Acute myeloid leukaemia	2A60	Phase 1/2	[6]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[7]
CD137 CAR-T Cell	DMHMC19	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[8]
ADG106	DM87H0S	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[10]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[13]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[14]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[15]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[16]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[17]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[18]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[19]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[20]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[21]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Co-stimulatory molecule 4-1BB (CD137)	TTPW9LJ	TNR9_HUMAN	Agonist	[2]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Agonist	[3]

References

• [1] ClinicalTrials.gov (NCT03922204) A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Merus.
• [3] Clinical pipeline report, company report or official report of Merus.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [6] ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
• [7] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [8] ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
• [9] Clinical pipeline report, company report or official report of Adagene.
• [10] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [11] Clinical pipeline report, company report or official report of Genmab.
• [12] Clinical pipeline report, company report or official report of Inhibrx.
• [13] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [16] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [18] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [19] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [20] National Cancer Institute Drug Dictionary (drug id 740856).
• [21] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [22] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.